Understanding why neuroscience is one of the most difficult areas of drug research because diseases are poorly understood and disease processes are difficult to measure objectively
Using meaningful data at scale (MDAS), digital endpoints and outcomes to provide new, clinically meaningful insights into the disease, completely change our ability to measure disease processes, and reliably determine whether new therapies are impacting these processes
Changing how we manage disease by changing outcomes for patients, and in turn driving better research for the development of next generation therapies
10.15Speed Networking Session
11.15 Patient-Centric Trials – What’s next?
Head of Clinical Strategy & Operations , Novartis Institutes for Biomedical Research (NIBR)
Discussing how remote trials are transforming clinical studies and supporting patientcentricity
Moving from purely home-based remote trials – how we incorporate the patients’ own GP on these efforts?
11.45 Sampling Approaches in Patient-Centric Trials
VP, Digital & Analytics Technologies , Merck & Co.
Discussing the need for patient-focused tools in clinical research
Exploring approaches for smart, home or outpatient sampling
Data management (privacy, security & data management)
Enhancing data collection with wearables & mobile applications
15.25Afternoon Refreshments & Networking
15.55 Accelerating Patient Recruitment & Managing Clinical Data with Digital Tools
Professor of e-Health Innovation & Head of Research - Institute of Digital Healthcare (IDH) , University of Warwick
Overviewing EU FP7 Project Transform – utilising digital tools for patient recruitment
Enhancing clinical data management – the C.U.R.e Framework
Presenting implementation case-studies
16.25 Enabling World-Class Clinical Trials Using National NHS Data
Executive Director of Data, Insights & Statistics , NHS Digital
Exploring how the NHS Digital is working with HDR UK’s Oxford University site, and the National Institute for Health Research, to develop innovative clinical trial services
Using national NHS data, to support rapid, efficient trials that meet the needs of regulators (such as the MHRA and FDA) and NHS patients, while protecting individuals’ data rights
Seeing the benefits from the pilots of these services, that specifically support clinical trial cohort feasibility, selection and identification, and how they can be utilised by life sciences industry, to deliver more efficient trials
16.55Chair’s Closing Remarks
Executive Director - Global Program Lead for Data & Digital , Novartis
Amba Hotel Marble Arch
Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.